Taysha Gene Therapies Inc To Host Virtual Key Opinion Leader (KOL) Webinar On TSHA-102 For Treatment Of Rett Syndrome Call Transcript
Good morning, and welcome to Taysha Gene Therapies Rett Syndrome Investor Day. (Operator Instructions)
Today, we will provide an overview of Rett syndrome, hear from our patient advocate and discuss the TSHA-102 program and clinical development strategy. Joining the call today is RA Session II, Taysha's President, Founder and CEO; Dr. Jeffrey Neul, our key opinion leader, guest speaker from Vanderbilt University Medical Center; Monica Coenraads, Chief Executive Officer of Rett Syndrome Research Trust; Dr. Steven Gray, Associate Professor in the Department of Pediatrics at UT Southwestern and Chief Scientific Adviser at Taysha; and Dr. Suyash Prasad, Taysha's Chief Medical Officer and Head of R&D.
Next slide, please. Before we begin, please note that this presentation will include forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may include the expected timing and results of clinical trials for our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |